SPR Therapeutics has obtained CE mark approval to market its Smartpatch Peripheral Nerve Stimulation device in Europe. The technology, which can be used for a maximum of 30 days, uses peripheral nerve stimulation to treat chronic shoulder pain. The company also is pursuing FDA approval for use of the device in treating post-amputation and post-stroke pain.
EU approves SPR's nerve stimulation device for chronic shoulder pain
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|